Le Lézard
Classified in: Health
Subjects: PDT, BFA

POP ON VENEERS ANNOUNCES $120 OFF FOR THE HOLIDAY SMILE SALE


NEW YORK, Oct. 17, 2022 /PRNewswire/ -- Pop On Veneers is making it so easy for everyone to have their smile ready for this holiday season? no more hiding from the camera! With the new Holiday Smile Sale, customers will be smiling with confidence in all their holiday pictures.

With Pop On Veneers' Holiday Smile Sale, customers can smile with confidence in their holiday photos for $120 off.

Customers may choose to have their digital impressions made in-person at the brand-new Pop On storefront in Manhattan, New York. Alternatively, customers can choose to make the impressions at-home with a kit provided by the company. In either case, Pop On Veneers will design 100% custom-made removable veneers that Pop On over existing teeth, transforming into the smile of their dreams? all in time for the holiday season!

"I used to be afraid to smile in family photos for the holidays, and I know this year I'm going to be grinning cheek to cheek," says customer Ryan after popping on his veneers. "It gave me so much confidence,'' says customer Amanda while wearing her Pop On Veneers. "I'm smiling like a big old cheese in so many pictures now... and I want to take pictures with everybody. I'm usually the one behind the camera, now I'm in front of it," she adds.

Pop On Veneers is the number one way to get a smile you love this holiday season. For those who have been self conscious about taking photos for holiday cards, and for those who have been hesitant to take photos at holiday dinners, Pop On Veneers is an affordable, pain-free solution. Pop On Veneers delivers life-changing smiles in time for one of the most memorable times of the year.

Whether you're missing teeth, have chipped teeth, or looking for a brighter smile, Pop On Veneers will deliver a 100% custom-made smile to your doorstep without shaving your natural teeth. A Pop On smile costs just a fraction of corrective dental procedures, and is a completely pain-free process. Pop On Veneers prides itself on its accessibility: the already affordable cost comes with several payment plan options, ensuring that everyone gets the opportunity to have a smile they love.

Find Pop On Veneers on:
PopOnVeneers.com
Instagram here
Facebook here
Youtube here

Contact: Grace French
Email: [email protected]

SOURCE Pop On Veneers


These press releases may also interest you

at 05:09
Sectra publishes Annual Report and Sustainability Report for 2023/2024
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
India-Based Dhiti Omics is Now Live on SOPHiA DDMtm
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI: Appointment of Adviser
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

More news about Health...


News published on and distributed by: